PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.28%
Both yoy net incomes decline, with AXSM at -39.04%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.30%
Some D&A expansion while AXSM is negative at -15.49%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
41.15%
SBC growth well above AXSM's 30.15%. Michael Burry would flag major dilution risk vs. competitor’s approach.
170.16%
Well above AXSM's 79.45% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
170.16%
Growth well above AXSM's 198.79%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
169.42%
Some yoy increase while AXSM is negative at -5.58%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-4.39%
Both yoy CFO lines are negative, with AXSM at -22.40%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
94.15%
CapEx growth well above AXSM's 72.12%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AXSM's 72.12%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-97.06%
Both yoy lines negative, with AXSM at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.